PhagoMed
PhagoMed develops precision therapies for chronic bacterial infections. Its lead program, PM-477, targets Recurrent Bacterial Vaginosis (rBV), a chronic vaginal disease that affects 100 million women across the globe. To treat rBV, PhagoMed invented a phage-based lysin that targets only the disease-causing bacteria and preserves the beneficial vaginal microbiome. The platform technology is now being extended to further chronic diseases.